Teleflex (TFX)
NYSE:TFX
Want to see TFX full AI Analyst Report?
TFX Stock Chart & Stats
$131.58
-$2.38(-1.33%)
At close: 4:00 PM EST
$131.58
-$2.38(-1.33%)
Day’s Range― - ―
52-Week Range$100.18 - $139.67
Previous CloseN/A
Volume73.33K
Average Volume (3M)705.88K
Market Cap
$5.78B
Enterprise Value$5.56B
Total Cash (Recent Filing)$309.41M
Total Debt (Recent Filing)$2.69B
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Jul 30, 2026EPS Estimate
1.27Next Dividend Ex-DateN/A
Dividend Yield1.11%
Share Statistics
EPS (TTM)-22.80
Shares Outstanding44,270,210
10 Day Avg. Volume582,262
30 Day Avg. Volume705,883
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.74
Price to Sales (P/S)2.73
P/FCF Ratio22.19
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue1.98
Enterprise Value/Gross Profit3.71
Enterprise Value/Ebitda-62.81
Forecast
1Y Price Target
$147.00Price Target Upside11.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)6.7
Revenue Forecast (FY)$2.29B
Bulls Say, Bears Say
Bulls Say
Recurring Consumables & Diversified PortfolioTeleflex’s business is anchored in single-use medical devices across multiple high-acuity therapy areas. Recurring consumable demand tied to procedure volumes creates durable revenue streams and repeat purchasing, supporting revenue resilience and predictable installed-base driven cash flow over months to years.
Positive Free Cash Flow GenerationDespite accounting losses, Teleflex is producing meaningful operating and free cash flow, which provides durable financial flexibility. Positive FCF supports debt reduction, opportunistic buybacks, restructuring funding, and R&D investment without reliance on equity issuance, strengthening long‑term capital options.
Portfolio Reshaping With Clear Capital PlanThe combination of M&A rebalancing and planned divestitures refocuses Teleflex on higher‑acuity vascular, interventional and surgical end markets. Realizing proceeds and executing buyback/deleveraging will structurally improve interest expense, capital allocation discipline, and the firm’s ability to invest in targeted growth initiatives.
Bears Say
Sharp Profitability DeteriorationA sustained net loss and negative EBITDA materially weaken returns and reduce retained earnings, limiting reinvestment capacity and harming ROE. If below‑the‑line charges persist, management’s ability to fund growth from operations and execute on strategic initiatives without further balance sheet moves will be constrained.
Material Margin Compression DriversTariffs, supplier remediation costs, higher logistics and a lower‑margin acquisition have compressed margins. Even if some are temporary, stranded costs and mix shifts can persist, reducing structural profitability and delaying the restoration of pre‑2024 margins until actions and divestitures fully take effect.
Divestiture Regulatory And Execution RiskRegulatory review or delayed closings would postpone expected $1.8B proceeds, slowing planned debt reduction and buybacks and extending stranded costs. Execution risk in carve‑outs and integration distractions can lengthen margin recovery timelines and impair strategic focus during the transition.
Teleflex News
TFX FAQ
What was Teleflex’s price range in the past 12 months?
Teleflex lowest stock price was $100.18 and its highest was $139.67 in the past 12 months.
What is Teleflex’s market cap?
Teleflex’s market cap is $5.78B.
When is Teleflex’s upcoming earnings report date?
Teleflex’s upcoming earnings report date is Jul 30, 2026 which is in 45 days.
How were Teleflex’s earnings last quarter?
Teleflex released its earnings results on May 07, 2026. The company reported $1.39 earnings per share for the quarter, beating the consensus estimate of $1.214 by $0.176.
Is Teleflex overvalued?
According to Wall Street analysts Teleflex’s price is currently Undervalued.
Does Teleflex pay dividends?
Teleflex pays a Quarterly dividend of $0.34 which represents an annual dividend yield of 1.11%. See more information on Teleflex dividends here
What is Teleflex’s EPS estimate?
Teleflex’s EPS estimate is 1.27.
How many shares outstanding does Teleflex have?
Teleflex has 44,270,210 shares outstanding.
What happened to Teleflex’s price movement after its last earnings report?
Teleflex reported an EPS of $1.39 in its last earnings report, beating expectations of $1.214. Following the earnings report the stock price went up 6.857%.
Which hedge fund is a major shareholder of Teleflex?
Currently, no hedge funds are holding shares in TFX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Teleflex Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$147.00 (11.72% Upside)
$147.00 (11.72% Upside)
Blogger Sentiment
Bullish
TFX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.8%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
8.08%
12-Months-Change
Fundamentals
Return on Equity
-28.27%
Trailing 12-Months
Asset Growth
-5.31%
Trailing 12-Months
Company Description
Teleflex
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
TFX Company Deck
TFX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced call: management reported solid pro forma revenue growth, strategic progress on M&A, a large capital return plan and promising clinical trial enrollment, but results were tempered by significant margin pressure (470–510 bps declines), remediation and recall costs, stranded costs from planned separations, higher interest expense and temporary integration/disruption in Interventional. Management positioned many negatives as largely transient and highlighted expected improvement beginning in 2027.View all TFX earnings summariesTFX Stock 12 Month Forecast
Average Price Target
$147.00
▲(11.72% Upside)
Technical Analysis
Haemonetics
―
ICU Medical
―
Lemaitre Vascular
―
Merit Medical Systems
―
Bausch + Lomb Corporation
―
Ownership Overview
0.41% Insiders
41.07% Mutual Funds
20.04% Other Institutional Investors
16.21% Public Companies and
Individual Investors